First Human Immunology Challenge Symposium Announced By NIH's National Heart, Lung And Blood Institute's (NHLBI) Center For Human Immunology (CHI)

Main Category: Immune System / Vaccines
Article Date: 30 Aug 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

NIH's National Heart, Lung and Blood Institute's CENTER FOR HUMAN IMMUNOLOGY (CHI) announces the first Meeting the Human Immunology Challenge Symposium. This two-day meeting will be held September 3-4, 2009 on the NIH Campus.

This symposium is being supported by the Foundation for the National Institutes of Health, with sponsoring partners that include: Agilent, Amgen, BMS, Invitrogen, MedImmune, Novartis, and Pfizer.

There are several goals for this first meeting of the Center for Human Immunology (CHI). One aim is increasing the Institute's understanding of how CHI can play the most effective possible role in performing human immunologic studies in today's academic environment. In this regard, there will be discussions regarding clinical research challenges and opportunities in various areas of expertise.

An equally important goal is to provide information to the larger community on what tools, techniques, clinical, and intellectual resources are available in the CHI, with the hope that clinical/scientific collaboration between intramural NIH researchers and the extramural community can be fostered and developed.

This Symposium will also host representatives from several companies focused on this space as well as leadership from the National Heart, Lung and Blood Institute so it should be an excellent networking opportunity for academics and researchers and health care practitioners alike.

To register for this meeting, please go here.

About The Foundation For NIH

Established by the United States Congress to support the mission of the NIH - improving health through scientific discovery in the search for cures -- the Foundation for NIH is a leader in identifying and addressing complex scientific and health issues. It expedites or facilitates the potential for new discoveries by convening innovative public/private collaborative partnerships that leverage the diverse strengths of stakeholders including those from the scientific and research community, industry, academia, advocacy groups, foundations and philanthropy. The foundation is a non-profit, 501(c)(3) corporation, that raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.

For additional information about the Foundation for NIH, please visit: http://www.fnih.org.

Source
CHI

• Additional
• References
• Citations